Sunday 15 November 2026
Export BRVE’s income statement to Excel — free account
Braveheart Bio, Inc.
BRVE- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
19.62
0.88
−4.29%
Follow BRVE
Alert me
Braveheart Bio, Inc. (BRVE) P/E ratio
Braveheart Bio, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BRVE Braveheart Bio, Inc. | n/m |
| ZBIO Zenas BioPharma, Inc. compare | n/m |
| TRVI Trevi Therapeutics, Inc. compare | n/m |
| QURE uniQure N.V. compare | n/m |
| COAG Hemab Therapeutics Holdings, Inc. compare | n/m |
| FTRE Fortrea Holdings Inc. compare | n/m |
| AGIO Agios Pharmaceuticals, Inc. compare | n/m |
| ZYME Zymeworks Inc. compare | 39.5× |
| LYCA Lycia Therapeutics Inc. compare | — |
| Biotechnology industry median | 11.4× |
| Healthcare sector median | 25.3× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)